Resources Repository
-
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | North America | Social Determinants | Infectious Diseases | Evidence Synthesis | Culture/Society | Economics/Finance | Health/Medicine -
ArticlePublication 2022Child Health Inequity through Case Management of Under-Five Malaria in Nigeria: An ECEA
This study assesses the potential impact of subsidies covering the direct and indirect costs of …
This study assesses the potential impact of subsidies covering the direct and indirect costs of under-five malaria case management in Nigeria, utilizing an extended cost-effectiveness analysis (ECEA) and a decision tree model. Findings reveal that fully subsidizing medical, non-medical, and indirect costs could annually avert over 19,000 under-five deaths, 8,600 cases of catastrophic health expenditure (CHE), and US$187 million in out-of-pocket (OOP) spending. Per US$1 million invested, this translates to a significant reduction in under-five…
Cost-Effectiveness Analysis | Sub-Saharan Africa | Policy/Regulation | Infectious Diseases | Health Outcomes | Mathematical Models | Child/Nutrition | Health/Medicine -
ArticlePublication 2013Nutritional Policy Changes in SNAP: A Microsimulation and Cost-Effectiveness Analysis
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) …
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) or subsidizing fruits and vegetables purchased with SNAP. The target population was adults in the U.S. and the time horizon was 10 years. Results showed that banning SSB purchases using SNAP benefits would be expected to avert 510,000 diabetes person-years and 52,000 deaths from MIs and strokes over the next decade, with a savings of $2900 per QALY saved. A…
Cost-Effectiveness Analysis | North America | Policy/Regulation | Chronic Disease/Risk | Mathematical Models | Microsimulation | Economics/Finance | Food/Agriculture | Government/Law | Health/Medicine -
ArticlePublication 2019Cost-Effectiveness of U.S. National SSB Tax with a Multistakeholder Approach: Who Pays and Who Benefits
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) …
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) tax, overall and with stratified costs and benefits for nine distinct stakeholder groups. A microsimulation model (CVD PREDICT) was used to estimate cardiovascular disease reductions, quality-adjusted life years gained, and cost-effectiveness for U.S. adults aged 35 to 85 years, evaluating full and partial consumer price pass-through. Results showed that from both a health care and societal perspective, the SSB tax was…
Cost-Effectiveness Analysis | North America | Policy/Regulation | Chronic Disease/Risk | Microsimulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2019Health Impact and Cost-Effectiveness of SSB Taxes for Reducing Cancer Burden in the U.S.
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) …
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) tax policy for reducing obesity-related cancer in the U.S. A probabilistic cohort state-transition model, the Diet Cancer Outcome Model (DiCOM), was used to project the effect of a national $0.01 per ounce SSB excise tax on 13 obesity-associated cancers among U.S. adults age 20 and older over their lifetime. Cost-effectiveness was evaluated using both government affordability and societal perspectives. Results showed…
Cost-Effectiveness Analysis | North America | Policy/Regulation | Chronic Disease/Risk | Mathematical Models | Microsimulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2018Cost-Effectiveness of Financial Incentives and Disincentives for Improving Food Purchases and Health through SNAP
This analysis estimated the health impact, costs, and cost-effectiveness of food incentives, disincentives, or restrictions …
This analysis estimated the health impact, costs, and cost-effectiveness of food incentives, disincentives, or restrictions in the Supplemental Nutrition Assistance Program (SNAP). A microsimulation model (CVD-PREDICT) was used to compare three policy interventions: (1) a 30% incentive for fruits and vegetables (F&V), (2) a 30% F&V incentive with a restriction of sugar-sweetened beverages (SSBs), and (3) a broader incentive/disincentive program for multiple foods that also preserves choice (SNAP-plus). From a societal perspective, all three scenarios…
Cost-Effectiveness Analysis | North America | Policy/Regulation | Chronic Disease/Risk | Microsimulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2020Health Gains & Financial Risk Protection Afforded by Public Financing of Selected Malaria Interventions in Ethiopia: An ECEA
This article, published in the Malaria Journal, aims to estimate the expected health and financial …
This article, published in the Malaria Journal, aims to estimate the expected health and financial risk protection (FRP) benefits of universal public financing of key malaria interventions in Ethiopia. An extended cost-effectiveness analysis (ECEA) is used to estimate the potential health and FRP benefits of publicly financing a 10% increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and a hypothetical malaria vaccine. The results indicate that ACT, LLIN,…
Cost-Effectiveness Analysis | Sub-Saharan Africa | Social Determinants | Infectious Diseases | Priority Setting/Ethics | Health Systems | Health/Medicine -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Decision Analysis | Health/Medicine -
ArticlePublication 2018DALYS and QALYs – Does the Choice of Measure Matter?
This article discusses the measurement of health benefits as a key issue in health economic …
This article discusses the measurement of health benefits as a key issue in health economic evaluations. Authors adapted two previously published models, a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO) that reported outputs in QALYs to estimate DALYs in 3 settings, Argentina, Chile, and the United Kingdom. While the authors found that QALY gains were larger than DALYs avoided in all countries for HPV, differences using QALYs…
Cost-Effectiveness Analysis | Europe | Policy/Regulation | Infectious Diseases | Health/Medicine | Latin America & Caribbean